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Abstract
© 2015 International Spinal Cord Society Study design:Experimental study.Objective:Several
neuro-degenerative  disorders  such  as  Alzheimer’s  dementia,  Parkinson’s  disease  and
amyotrophic lateral sclerosis (ALS) are associated with genetic mutations, and replacing or
disrupting defective sequences might offer therapeutic benefits. Single gene delivery has so far
failed to achieve significant clinical improvements in humans, leading to the advent of co-
expression  of  multiple  therapeutic  genes.  Co-transfection  using  two  or  more  individual
constructs might inadvertently result in disproportionate delivery of the products into the cells.
To prevent this, and in order to rule out interference among the many promoters with varying
strength, expressing multiple proteins in equimolar amounts can be achieved by linking open
reading  frames  under  the  control  of  only  one  promoter.Setting:Kazan,  Russian
Federation.Methods:Here  we  describe  a  strategy  for  adeno-viral  co-expression  of  vascular
endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) interconnected through
picorna-viral 2A-amino-acid sequence in transfected human umbilical cord blood mono-nuclear
cells  (hUCB-MCs).Results:Presence  of  both  growth  factors,  as  well  as  absence  of  immune
response to 2A-antigen, was demonstrated after 28–52 days. Following injection of hUCB-MCs
into ALS transgenic mice, co-expression of VEGF and FGF2, as well as viable xeno-transplanted
cells, were observed in the spinal cord after 1 month.Conclusion:These results suggest that
recombinant adeno-virus containing 2A-sequences could serve as a promising alternative in
regenerative medicine for the delivery of therapeutic molecules to treat neurodegenerative
diseases,  such  as  ALS.Spinal  Cord  advance  online  publication,  6  October  2015;
doi:10.1038/sc.2015.162.
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